PMVP Stock — Pmv Pharmaceuticals Inc

Pmv Pharmaceuticals Inc (PMVP)

Updated October 16, 2026.

PMVP is a Stock. Total return is -96.8% over the past 6.1 years, 248.5 points behind SPY at 151.7%.

PMV Pharmaceuticals is a precision oncology company developing small molecule therapies targeting p53 mutations and related cancers, with its lead program rezatapopt currently in Phase 2 clinical trials. The company does not currently distribute dividends to shareholders. This security may appeal to investors seeking exposure to clinical-stage biopharmaceutical development rather than current income.

PMVP performance versus SPY

Price and return data through 2026-10-16.

Total return is -96.8% over the past 6.1 years, 248.5 points behind SPY at 151.7%. Over the past year its total return — price change plus distributions reinvested — is -16.0%. Its deepest 1-year drawdown was 41.7%.

PMVP key facts

Asset type

Stock

Asset class

Equity

Inception date

09/25/2020

Distribution frequency

None

Last close

$1.21 (as of 2026-10-16)

Market cap

$91,370,800

Average volume

357039.0

Beta

1.354

Payout ratio

0.0%

EPS

$-1.42

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

PMVP risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 41.7%.

Who may consider PMVP — and who may not

It is a weaker fit for investors who need monthly cash flow (PMVP does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on PMVP

• All tickers starting with P

Tagged: Healthcare.

Frequently asked questions